Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer
Journal of Clinical Investigation · 17.08.2026 · 136 (16)
DOI: 10.1172/jci203835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 09.06.2026. Verfasst von Rhea Sahu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Epigenesis, Genetic, Neoplasm Proteins. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CRUK.
Abstract (Originalsprache)
Men with advanced prostate cancer are typically treated with androgen deprivation therapy, but most ultimately develop resistance and incurable disease (e.g., castration-resistant prostate cancer, CRPC). The majority of CRPCs overexpress the epigenetic enzyme EZH2 and harbor alterations in the PI3K pathway, providing 2 targetable pathways outside of the androgen receptor. Here, we show that EZH2 inhibitors synergize with PI3K, AKT, or mTORC1 inhibitors to kill CRPC in vitro and promote tumor regression in vivo. Strikingly, these agents trigger a catastrophic energy crisis by cooperatively suppressing glycolysis, the TCA cycle, and oxidative phosphorylation before cell death. EZH2 and PI3K pathway inhibitors achieve this by respectively inhibiting 2 key regulators of metabolism, MYC and HIF-1A, while derepressing a proapoptotic stress sensor. Together, these studies reveal a promising therapeutic strategy for CRPC and demonstrate how metabolic plasticity can be fatally impaired by cotargeting upstream oncogenic nodes that converge on this important process. This study describes a promising therapeutic strategy for advanced prostate cancer that triggers metabolic collapse of tumors by combining agents suppressing epigenetic and oncogenic enzymes
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Medicine and.
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
- Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom.
Förderung
- CRUK
Zitieren
APA
Sahu, R., Enos, M., Sharma, S., Schade, A. E., Gardner, A., Yoshinaga, A., Indeglia, A., Minogue, E., Hu, S., Kurmi, K., Joshi, S., Schmidt, D. R., Yaffe, S., Nguyen, V. T., Xie, F., Balk, S. P., Vander Heiden, M. G., Helin, K., Haigis, M. C., & Cichowski, K. (2026). Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer. Journal of Clinical Investigation, 136(16). https://doi.org/10.1172/jci203835
Vancouver
Sahu R, Enos M, Sharma S, Schade AE, Gardner A, Yoshinaga A, et al. Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer. Journal of Clinical Investigation. 2026;136(16). doi:10.1172/jci203835
BibTeX
@article{Sahu2026,
author = {Sahu, Rhea and Enos, Miriam and Sharma, Swastika and Schade, Amy E and Gardner, Alycia and Yoshinaga, Akiko and Indeglia, Alexandra and Minogue, Eleanor and Hu, Songhua and Kurmi, Kiran and Joshi, Shakchhi and Schmidt, Daniel R and Yaffe, Samkyu and Nguyen, Van Tm and Xie, Fang and Balk, Steven P and Vander Heiden, Matthew G and Helin, Kristian and Haigis, Marcia C and Cichowski, Karen},
title = {Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {16},
doi = {10.1172/jci203835}
}
EUVIMED